New Approaches Promise to Improve Local Ewing Sarcoma Results

Ian J. Cohen*, Shifra Ash

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The study by Whelan and colleagues showed that addition of busulfan and melphalan conditioning and autologous stem cell rescue to conventional EURO-E.W.I.N.G STUDY chemotherapy in local nonmetastatic Ewing sarcoma improves prognosis. However, almost 30% of these study patients will have relapsed before this stage of therapy is reached, and 78% of his patients were at high risk because of inadequate response to the initial chemotherapy given. Further improvement could be achieved by the integration of other novel advances with this approach. Ash and colleagues have shown that the separation of such cases into high- and low-risk groups by using CD56 negativity of the tumor cells is an improvement over current methods with a 100% 10-year progression-free survival in CD56- nonpelvic local isolated Ewing sarcoma patients. Their patients were treated on the SCMCIE 94 protocol, associated with no relapses before 30 months in 24 consecutive patients independent of the CD status. Integration of these novel approaches in diagnosis and treatment would allow truly high-risk patients, who would benefit from the procedure, to reach the busulfan and melphalan stage of therapy and delineate those patients who can be cured without such therapy. Details of the SCMCIE 94 protocol are given and the possible reasons for the different relapse patterns are discussed.

Original languageEnglish
Pages (from-to)280-284
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Issue number6
StatePublished - 1 Aug 2022


  • CD56
  • Ewing
  • SCMCIE 94
  • integration
  • therapy


Dive into the research topics of 'New Approaches Promise to Improve Local Ewing Sarcoma Results'. Together they form a unique fingerprint.

Cite this